[go: up one dir, main page]

MX2019015007A - Composiciones inmunogénicas que comprenden los polipéptidos derivados de la leucocidina de staphylococcus aureus luka y lukb. - Google Patents

Composiciones inmunogénicas que comprenden los polipéptidos derivados de la leucocidina de staphylococcus aureus luka y lukb.

Info

Publication number
MX2019015007A
MX2019015007A MX2019015007A MX2019015007A MX2019015007A MX 2019015007 A MX2019015007 A MX 2019015007A MX 2019015007 A MX2019015007 A MX 2019015007A MX 2019015007 A MX2019015007 A MX 2019015007A MX 2019015007 A MX2019015007 A MX 2019015007A
Authority
MX
Mexico
Prior art keywords
immunogenic compositions
staphylococcus aureus
lukb
luka
derived polypeptides
Prior art date
Application number
MX2019015007A
Other languages
English (en)
Inventor
Mohammad Javad Aman
Thomas Kort
Nils Williston
Shweta Kailasan
Hatice Karauzum
Rajan P Adhikari
Original Assignee
Integrated Biotherapeutic Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Integrated Biotherapeutic Vaccines Inc filed Critical Integrated Biotherapeutic Vaccines Inc
Publication of MX2019015007A publication Critical patent/MX2019015007A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción proporciona composiciones inmunogénicas útiles en la prevención y el tratamiento de infecciones por Staphylococcus aureus. En particular, la descripción proporciona métodos para inducir una respuesta inmunitaria contra un S. aureus que expresa LukAB, métodos para prevenir o tratar infecciones por S. aureus y una composición para prevenir o tratar infecciones por S. aureus.
MX2019015007A 2017-06-13 2018-06-13 Composiciones inmunogénicas que comprenden los polipéptidos derivados de la leucocidina de staphylococcus aureus luka y lukb. MX2019015007A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762518641P 2017-06-13 2017-06-13
PCT/US2018/037376 WO2018232014A1 (en) 2017-06-13 2018-06-13 Immunogenic compositions comprising staphylococcus aureus leukocidin luka and lukb derived polypeptides

Publications (1)

Publication Number Publication Date
MX2019015007A true MX2019015007A (es) 2020-08-06

Family

ID=64660858

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019015007A MX2019015007A (es) 2017-06-13 2018-06-13 Composiciones inmunogénicas que comprenden los polipéptidos derivados de la leucocidina de staphylococcus aureus luka y lukb.

Country Status (7)

Country Link
US (1) US11421021B2 (es)
EP (1) EP3638286A4 (es)
CN (1) CN110913883A (es)
AU (1) AU2018285857B2 (es)
CA (1) CA3066450A1 (es)
MX (1) MX2019015007A (es)
WO (1) WO2018232014A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020273471A1 (en) 2019-05-14 2021-12-23 The University Of Chicago Methods and compositions comprising Staphylococcus protein A (SpA) variants
US20220362368A1 (en) 2019-10-02 2022-11-17 Janssen Vaccines & Prevention B.V. Staphylococcus peptides and methods of use
US20240050546A1 (en) * 2020-09-28 2024-02-15 Janssen Pharmaceuticals, Inc. Variant staphylococcus aureus luka and lukb polypeptides and vaccine compositions
EP4313303A4 (en) * 2021-04-02 2025-02-26 Janssen Pharmaceuticals, Inc. VACCINE COMPOSITIONS FROM STAPHYLOCOCCUS AUREUS
CN116078360B (zh) * 2023-03-07 2023-06-23 佛山市博新生物科技有限公司 一种清除白细胞及致病抗体的吸附纤维膜及其制备方法
CN119431528B (zh) * 2024-10-28 2025-10-14 中国人民解放军陆军军医大学 一种金黄色葡萄球菌毒素LukG抗原表位肽及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US20050008633A1 (en) 2003-05-19 2005-01-13 Advanced Inhalation Research Inc. Chemical and physical modulators of bioavailability of inhaled compositions
EP3444268B1 (en) * 2010-05-05 2021-12-15 New York University Staphylococcus aureus leukocidins, therapeutic compositions, and uses thereof
PL2668208T3 (pl) * 2012-04-17 2015-12-31 Arsanis Biosciences Gmbh Krzyżowo reaktywne przeciwciało rozpoznające Staphylococcus aureus
JP2015517463A (ja) * 2012-05-02 2015-06-22 ニューヨーク・ユニバーシティ 黄色ブドウ球菌感染および関連状態を処置および予防する方法
BR112015028650A2 (pt) * 2013-05-21 2017-09-19 Arsanis Biosciences Gmbh UM ANTÍGENO ISOLADO PARA LEUCOCIDINA DE S. AUREUS, UM ANTICORPO LIGANTE ESPECÍFICO PARA O ANTÍGENO, E UM COMPLEXO CD11b/CD18 HUMANO PARA UTILIZAÇÃO EM UM MÉTODO ANALÍTICO
CA2931327A1 (en) * 2013-12-19 2015-06-25 Arsanis Biosciences Gmbh Antibodies directed against the lukgh (lukab) toxin of staphylococcus aureus and antibody sequences
EP3302532A4 (en) * 2015-06-05 2019-01-09 New York University COMPOSITIONS AND METHODS FOR BIOLOGICAL ACTIVE AGGREGATES AGAINST STAPHYLOKOKEN

Also Published As

Publication number Publication date
EP3638286A1 (en) 2020-04-22
EP3638286A4 (en) 2021-03-10
CN110913883A (zh) 2020-03-24
WO2018232014A1 (en) 2018-12-20
US11421021B2 (en) 2022-08-23
US20200317759A1 (en) 2020-10-08
CA3066450A1 (en) 2018-12-20
AU2018285857B2 (en) 2022-10-06
AU2018285857A1 (en) 2020-01-02

Similar Documents

Publication Publication Date Title
MX2019015007A (es) Composiciones inmunogénicas que comprenden los polipéptidos derivados de la leucocidina de staphylococcus aureus luka y lukb.
EP4282489A3 (en) Treatment of clostridium difficile infection
WO2015181356A8 (en) Vaccine composition against streptococcus suis infection
MX2022006525A (es) Activo de polipeptidos de lisina contra bacterias gram-negativas.
PH12020500080A1 (en) Senecavirus a immunogenic compositions and methods thereof
WO2016179440A3 (en) Antimicrobial therapy
WO2016109689A3 (en) Derivatives and methods of treating hepatitis b infections
GB202215998D0 (en) Treating & preventing microbial infections
WO2016108045A3 (en) Antimicrobial compounds, compositions and methods
PH12019502915A1 (en) Immunogenic compositions
WO2015110969A3 (en) Nitrogen containing compounds and their use as antibacterial agents
WO2016004513A8 (en) Anti-bacterial pyruvate kinase modulator compounds, compositions, uses and methods
PH12016502003A1 (en) Novel bacteriophage and composition containing same
WO2017075188A3 (en) Methods of using anti-alpha toxin antibody
MX2021002909A (es) Vacunas de proteinas de fusion neumococicas.
MX2017012535A (es) Compuestos hetorociclicos novedosos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
WO2018170238A3 (en) Methods and compositions for inducing immune responses against clostridium difficile
MX2017014080A (es) Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
GB2568440A (en) Modified factor H binding protein
PH12021552875A1 (en) METHODS AND COMPOSITIONS COMPRISING STAPHYLOCOCCUS PROTEIN A (SpA) VARIANTS
MY183483A (en) Ophthalmic solution for treating ocular infection comprising levofloxacin or salt thereof or solvate of the same, method for treating ocular infection, levofloxacin or salt thereof or solvate of the same, and use thereof
MA39955A (fr) Compositions désinfectantes et antimicrobiennes, en particulier pour le domaine vétérinaire
PH12019502145A1 (en) Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredient
WO2019070709A8 (en) Compounds for treating or preventing flavivirus infections
GB2558090A (en) Combination of zinc pyrithione and silver sulfadiazine for the prevention and treatment of microbial infections